ReviewJournal of hematology & oncology2024
Small molecule inhibitors targeting m
Review in Journal of hematology & oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- Targeting the SETD2-FTO-KIT pathway as a pharmacological strategy for TKI-refractory GIST.Acta pharmaceutica Sinica. B · 2026Article
- Decoding the RNA Shield: HNRNPC and YTHDF2 Act as Guardians of Neurons in Parkinson's Disease.Neurotoxicity research · 2026Review
- FTO-CHRM3 axis regulates multiple myeloma progression: a machine learning-based identification.Annals of hematology · 2026Article
- Ribosome Biogenesis and Translational Control in Skeletal Muscle Atrophy and Hypertrophy: Mechanisms and Therapeutic Perspectives.Biomolecules · 2026Review
- M6AREG 2.0: the landscape of m6A-centered crosstalk with diverse epigenetic regulation.Nucleic acids research · 2026Article
- RNA variation as the driver of genomic efficiency and phenotypic complexity.International journal of biological sciences · 2026Review
- The m6A Reader YTHDF3 Promotes Glioma Progression by Regulating the m6A Modification of lncRNA-PAR5.Analytical cellular pathology (Amsterdam) · 2026Article
- Research progress on the characteristics and functions of m6A modification in lung cancer tumor stem cells.American journal of cancer research · 2026Review
- m6A RNA methylation in sepsis-induced cardiomyopathy: direct cardiac mechanisms, emerging therapeutic targets, and translational gaps.Frontiers in medicine · 2026Review
- Targeting cancer stem cell plasticity and tumor microenvironment crosstalk: a comprehensive review.Discover oncology · 2025Review
- The Central Role of m6A as Epigenetic Regulator in Metabolic Disorders of Therapeutic Potential and Clinical Implications.Molecular neurobiology · 2025Review
- The applications of single-cell multiomics in drug screening.Pharmaceutical science advances · 2025Review
- Unveiling the role of m6A modification in esophageal cancer: a new frontier in tumor innate interferon immunity.Cancer cell international · 2025Review
- The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications.Biomarker research · 2025Review
- Identification of a m6A-immune-related risk model for predicting prognosis, immune microenvironment, and drug responses in acute myeloid leukemia.Scientific reports · 2025Article
- m6A-mediated silencing of RNF41 by METTL3/YTHDC1 disrupts autophagy to drive intervertebral disc degeneration.Cell biology and toxicology · 2025Article
- The deubiquitinase USP9X and E3 ligase WWP1 orchestrate IGF2BP2 ubiquitination homeostasis to drive TNBC progression and cisplatin sensitivity.Cell death & disease · 2025Article
- mCells · 2025Review
- Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
As the most common form of epigenetic regulation by RNA, N
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.